CAR T-cell therapy (Protanbio)

N/A

Report date: 2025/03/14 16:51:15

Base Information

Drug NameCAR T-cell therapy (Protanbio)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSeoul National University

China Registration ClassN/A

Develop Information

Active CompaniesProtanbio Inc

Inactive CompaniesSeoul National University

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A